Clinical Trial Update: A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease [Phase 1, Phase 2]

View source ↗

Summary

Genentech is conducting a Phase 1/2 study to assess the safety and effects of inhaled GDC-6988 in people with muco-obstructive diseases, including non-cystic fi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• GDC-6988

Snippet

Sponsor: Genentech, Inc. | Conditions: Non-cystic Fibrosis Bronchiectasis, Chronic Obstructive Pulmonary Disease | Phase 1, Phase 2 | Status: RECRUITING